Spener Hall

SGLT2 inhibitors – Why would you not use one?

Evening Session

Danilo Verge (AstraZeneca), Jiten Vora (UK/AstraZeneca)
Opening and welcome
Mikhail Kosiborod (USA)
Risk management in diabetes
Richard Holt (UK)
What can we ask from an antidiabetic treatment in 2018?
Juris Meier (Germany)
What prevents us from optimal treatment?
Discussion and Q&A
Jiten Vora (UK/AstraZeneca)
Summary and close
Symposia by: